Method for detecting residual impurities in bilastine

Through the combined use of liquid chromatography-mass spectrometry, the problem of by-product residue detection in bilastine was solved, and 1-(2-ethoxy-ethyl)-2-piperidine-4- in bilastine was achieved. The high sensitivity and accurate detection of base-1H-benzimidazole provides a basis for monitoring the quality of raw materials.

CN118961946APending Publication Date: 2024-11-15SHIJIAZHUANG NO 4 PHARMACEUTICAL CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411296045.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

During the Bilastine production process, the by-product 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole may remain in the final product, and there is a lack of effective detection methods.

Method used

Using liquid chromatography-mass spectrometry technology, specific liquid chromatography and mass spectrometry conditions are set, including C18 chromatography column, column temperature 27-33℃, column flow rate 0.95-1.05mL/min, mobile phase A is 1g/ L's aqueous ammonium formate solution and mobile phase B are acetonitrile, ESI ion source, single ion scanning mode and triple quadratic rod tandem mass spectrometer to achieve accurate detection of residual impurities in Bistine.

Benefits of technology

This method has high sensitivity, good linear relationship and high accuracy, and can accurately detect 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in Bilastine Trace amount provides the basis for quality monitoring of Bilastin raw materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961946A_ABST
    Figure CN118961946A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting residual impurities in bilastine. According to the method disclosed by the invention, the accurate quantitative detection of the residual impurity 1-(2-ethyoxyl-ethyl)-2-piperidine-4-yl-1H-benzimidazole in the bilastine raw material medicine is realized by adopting a detection method combining liquid chromatography and mass spectrometry. The detection method has the advantages of strong specificity, high sensitivity, good linear relationship, accurate and reliable quantification, good precision and durability, and can be used for trace detection of the residual impurity 1-(2-ethyoxyl-ethyl)-2-piperidine-4-yl-1H-benzimidazole in the bilastine bulk drug. The method is used as a basis for monitoring the quality of the bilastine bulk drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting residual impurities in bilastine. Background Art

[0002] Bilastine is an oral non-sedating histamine H1 receptor antagonist developed by the Spanish FAES Pharmaceutical Company. It can selectively act on peripheral histamine receptors and has no effect on other histamine receptors. It does not have the sedative effect on the central nervous system and the toxic side effects on the cardiovascular system that commonly used antihistamines have. It has good tolerance, safety and high bioavailability. The English name of bilastine is bilastine, and its chemical name is 2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]-phenyl]-2-methylpropionic acid. The structural formula is shown in Formula I:

[0003]

[0004] However, in the process of producing bilastine, a byproduct 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole (structural formula shown in Formula II) is produced in the intermediate step, and the byproduct may remain in the final product. Therefore, a method for accurately detecting 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in bilastine raw materials is needed, but no report on the detection method of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in bilastine raw materials has been found.

[0005] Summary of the invention

[0006] In view of this, the present invention provides a method for detecting residual impurities in bilastine. The detection method successfully realizes the accurate determination of the above-mentioned residual impurities in bilastine by liquid chromatography-mass spectrometry technology, and the detection method has strong specificity, high sensitivity, good linear relationship and high accuracy, and can be used as a basis for quality monitoring of bilastine raw materials.

[0007] In order to solve the above technical problems, the present invention provides a method for detecting residual impurities in bilastine, wherein the liquid chromatography conditions in the liquid chromatography-mass spectrometry method include:

[0008] Chromatographic column: C18 column;

[0009] Column temperature: 27-33°C;

[0010] Column flow rate: 0.95~1.05mL / min;

[0011] Mobile phase A: 1 g / L ammonium formate aqueous solution;

[0012] Mobile phase B: acetonitrile;

[0013] Wherein, the residual impurity is 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole.

[0014] The invention provides a method for detecting residual impurities (1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole) in bilastine. By setting a specific liquid chromatography, the residual impurities can be detected from bilastine. The detection method has strong specificity and high sensitivity (the detection limit concentration is as low as 1.85 ng / mL), and provides a basis for quality monitoring of bilastine raw materials.

[0015] In combination with the first aspect, the chromatographic column includes XBridge C18 and YMC-Triart C18, preferably XBridge C18.

[0016] In combination with the first aspect, the specification of the chromatographic column is 250mm*4.6mm*5μm.

[0017] In combination with the first aspect, isocratic elution is adopted, and the volume proportion of the mobile phase B in the mobile phase is 28% to 32%, preferably 30%.

[0018] In combination with the first aspect, in liquid chromatography detection, the injection volume is 1 μL.

[0019] In combination with the first aspect, the mass spectrometry conditions in the liquid chromatography-mass spectrometry method include:

[0020] Ion mode: ESI ion source, positive ion scanning mode;

[0021] Detection mode: single ion scanning detection (Q1 MI);

[0022] Curtain gas (CUR): 40psi;

[0023] Declustering voltage (DP): 60 V;

[0024] Injection voltage (EP): 5~15V;

[0025] Collision chamber ejection voltage (CXP): 10 volts;

[0026] Quantitative ion: 274.1.

[0027] In combination with the first aspect, the mass spectrometry conditions in the liquid chromatography-mass spectrometry method further include:

[0028] Mass spectrometer: triple quadrupole tandem mass spectrometer;

[0029] Ionization voltage (IS): 5000V;

[0030] Ion source gas 1 (GS1): 55 psi;

[0031] Auxiliary heating gas (GS2): 55psi;

[0032] Ionization temperature (TEM): 550°C.

[0033] The method has good linear relationship in quantitative detection (linear correlation coefficient R>0.9995), is accurate and reliable (recovery rate is between 85.72% and 97.99%), and has good precision and durability. All method validations meet the requirements and can be used for trace detection of potential process impurity 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in bilastine raw materials.

[0034] In conjunction with the first aspect, the method for detecting residual impurities in bilastine specifically comprises the following steps:

[0035] A blank solution, a standard series of reference substance solutions and a test solution of the bilastine raw material drug are prepared; the blank solution, the reference substance solution and the test solution are respectively detected by the liquid chromatography-mass spectrometry method; a reference substance standard curve is drawn, and the content of the residual impurities in the test solution is determined by the corresponding standard curve.

[0036] In combination with the first aspect, the blank solution, the reference solution and the test solution are all prepared with an acetonitrile aqueous solution with a volume fraction of 30%.

[0037] In combination with the first aspect, the concentration of residual impurities in the test solution is 6.16-153.90 ng / mL, and the above detection method provided by the present invention can accurately detect the concentration of residual impurities in the bilastine solution within the above range.

[0038] The beneficial effects obtained by the present invention are as follows: the detection method of liquid chromatography and mass spectrometry provided by the present invention can realize accurate detection of the residual impurity 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in the bilastine raw material drug, the detection method has strong specificity, high sensitivity, good linear relationship, can accurately and reliably quantify, and has good precision and durability, and can be used for trace detection of the residual impurity 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole in the bilastine raw material drug, as a basis for quality monitoring of the bilastine raw material drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 is the mass spectrum corresponding to the blank solution;

[0040] Figure 2 is the mass spectrum corresponding to the reference solution;

[0041] Figure 3 is the mass spectrum corresponding to the test solution;

[0042] Figure 4 This is a standard curve of the residual impurity 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole. DETAILED DESCRIPTION

[0043] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0044] In the following examples of the present invention, the 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole used was purchased from Jiangxi Yehong Pharmaceutical Company with a purity of 100%.

[0045] Example 1

[0046] This embodiment provides a method for detecting residual impurities in bilastine, which is detected by liquid chromatography-mass spectrometry; wherein:

[0047] (1) The chromatographic conditions of liquid chromatography are:

[0048] Chromatographic column: XBridge C18 column (250mm*4.6mm, 5μm) (other chromatographic columns with similar specifications and fillers are also acceptable);

[0049] Column temperature: 30°C;

[0050] Column flow rate: 1.00 mL / min;

[0051] Injection volume: 1 μL;

[0052] Mobile phase: Mobile phase A: 1 g / L ammonium formate aqueous solution, mobile phase B: acetonitrile, the volume ratio of mobile phase A to mobile phase B is 7:3.

[0053] (2) Mass spectrometry conditions are:

[0054] Mass spectrometer: triple quadrupole tandem mass spectrometer;

[0055] Ion mode: ESI ion source, positive ion scanning mode;

[0056] Detection mode: single ion scanning detection (Q1 MI);

[0057] Curtain gas (CUR): 40psi;

[0058] Declustering voltage (DP): 60 V;

[0059] Injection voltage (EP): 5~15V;

[0060] Collision chamber ejection voltage (CXP): 10 volts;

[0061] Ionization voltage (IS): 5000V;

[0062] Ion source gas 1 (GS1): 55 psi;

[0063] Auxiliary heating gas (GS2): 55psi;

[0064] Ionization temperature (TEM): 550°C;

[0065] Quantitative ion: 274.1.

[0066] (3) Preparation of reference solution and test solution:

[0067] Blank solution: 30% by volume acetonitrile aqueous solution.

[0068] Reference stock solution: Take an appropriate amount of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole, accurately weigh it, dissolve and dilute it with a 30% by volume acetonitrile aqueous solution to make a solution containing approximately 1500 ng of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole per 1 mL as the reference stock solution.

[0069] Reference substance solution: Accurately pipette 0.5 mL of reference substance stock solution into a 10 mL volumetric flask, add 30% by volume acetonitrile aqueous solution to dilute to the mark as the reference substance solution.

[0070] Test solution: Take about 10 mg of bilastine test sample, accurately weigh it, put it into a 10 mL volumetric flask, add 30% by volume acetonitrile aqueous solution to dissolve it and dilute it to the scale as the test solution.

[0071] Test example

[0072] According to the detection conditions of Example 1 and using the solution prepared in Example 1, the detection method was respectively investigated and verified in terms of specificity, linear relationship, sensitivity, accuracy and durability.

[0073] The specific detection process is as follows:

[0074] 1. Specificity test:

[0075] The blank solution, reference solution and test solution were measured respectively, and HPLC-MS was performed under the conditions of the proposed method, and the spectra were recorded. Figures 1 to 3 shown.

[0076] Depend on Figures 1 to 3 It can be seen that under the above detection conditions, other components or impurities in the blank solution and the test sample have no interference with the detection of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole, indicating that the detection method has good specificity.

[0077] 2. Linear relationship verification:

[0078] Weigh an appropriate amount of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole, accurately weigh it, dissolve it in a 30% by volume aqueous acetonitrile solution, and dilute it step by step to make a series of solutions containing approximately 6.16 ng, 15.39 ng, 46.17 ng, 76.95 ng, 107.73 ng, and 153.90 ng of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole per 1 mL as linear standard solutions.

[0079] Take each linear standard solution for HPLC-MS detection, and draw a standard curve (such as Figure 4 As shown), and the regression equation was calculated, and the results are shown in Table 1. From the results, it can be seen that 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole has a good linear relationship in the concentration range of 6.16 to 153.90 ng / mL.

[0080] Table 1 Linearity test results

[0081]

[0082] 3. Detection limit and quantification limit test:

[0083] Detection limit: The reference solution was measured and quantitatively diluted step by step with a 30% by volume aqueous acetonitrile solution. The detection limit was obtained by HPLC-MS detection with a signal-to-noise ratio of not less than 3:1. The results are shown in Table 2.

[0084] Limit of quantitation: The reference solution was measured and quantitatively diluted step by step with a 30% by volume aqueous solution of acetonitrile. The quantitation limit was obtained by HPLC-MS detection with a signal-to-noise ratio of not less than 10:1. The results are shown in Table 2.

[0085] Table 2 Detection limit and quantification limit test results

[0086]

[0087] It can be seen from Table 2 that the detection limit and quantification limit obtained by this detection method can meet the detection requirements.

[0088] 4. Precision test:

[0089] According to the obtained quantification limit, 6 solutions with concentrations equal to the quantification limit were prepared in parallel (referred to as solution 1 to solution 6), and HPLC-MS detection was performed respectively. The results are shown in Table 3.

[0090] Table 3 Precision test results

[0091]

[0092] From the test results in Table 3, it can be seen that the relative standard deviation of the peak area corresponding to the impurity 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole is less than 10%, indicating that the detection method provided by the present invention has good precision.

[0093] 5. Accuracy test:

[0094] The accuracy test of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole is expressed as recovery rate (%). The limit solutions of 60%, 100% and 140% of the impurity limit are respectively used as the recovery test samples. The specific preparation process of the required solution is as follows:

[0095] 60% limit recovery solution: Take about 10 mg of the test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.3 mL of the reference stock solution, add 30% volume fraction acetonitrile aqueous solution to dissolve and dilute to the scale as the low recovery solution. This solution should be prepared in triplicate.

[0096] 100% limit recovery solution: Take about 10 mg of the test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.5 mL of the reference stock solution, add 30% by volume acetonitrile aqueous solution to dissolve and dilute to the scale as the medium recovery solution. This solution should be prepared in triplicate.

[0097] 140% limit recovery solution: Take about 10 mg of the test sample, accurately weigh it, place it in a 10 mL volumetric flask, add 0.7 mL of the reference stock solution, add 30% by volume acetonitrile aqueous solution to dissolve and dilute to the scale as the high recovery solution. This solution should be prepared in triplicate.

[0098] The reference solution and each recovery solution were measured and tested by HPLC-MS, and the spectra were recorded. The recovery results are shown in Table 4. (Recovery (%) = (measured amount - original amount of test sample) / added amount × 100%).

[0099] Table 4 Accuracy test results

[0100]

[0101] As shown in Table 4, within the limit concentration range of 60% to 140%, the recovery rate of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole is between 85.72% and 97.99%, and the RSD is 5.08%, indicating that the detection method has good accuracy.

[0102] 6. Durability test:

[0103] The reference solution was measured respectively, and HPLC-MS detection was performed according to the following fine-tuning chromatographic conditions. The fine-tuning chromatographic conditions were: column flow rates were 1.05 mL / min and 0.95 mL / min, column temperatures were 33°C and 27°C, and the volume proportions of mobile phase B in the mobile phase solution were 32% and 28%, respectively. The durability of the method for detecting 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole was investigated according to the above-mentioned fine-tuning chromatographic conditions, and the test results are shown in Table 5.

[0104] Table 5 Durability test results

[0105]

[0106] As shown in Table 5, fine-tuning the chromatographic conditions had no effect on the detection of 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole, indicating that the detection method has good durability.

[0107] What is described above is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for detecting residual impurities in bilastine, characterized in that, Liquid chromatography-mass spectrometry is used, and the liquid chromatography conditions in the liquid chromatography-mass spectrometry method include: Chromatographic column: C18 column; Column temperature: 27-33°C; Flow rate: 0.95~1.05mL / min; Mobile phase A: 1 g / L ammonium formate aqueous solution; Mobile phase B: acetonitrile; Wherein, the residual impurity is 1-(2-ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole.

2. The method for detecting residual impurities in bilastine as claimed in claim 1, characterized in that, The chromatographic columns include XBridge C18 and YMC-Triart C18.

3. The method for detecting residual impurities in bilastine as claimed in claim 2, characterized in that, The specification of the chromatographic column is 250mm*4.6mm*5μm.

4. The method for detecting residual impurities in bilastine according to claim 1, characterized in that, Isocratic elution is adopted, and the volume proportion of the mobile phase B in the mobile phase is 28% to 32%.

5. The method for detecting residual impurities in bilastine according to claim 1 or 2, characterized in that, In the liquid chromatography detection, the injection volume was 1 μL.

6. The method for detecting residual impurities in bilastine according to any one of claims 1 to 5, characterized in that: The mass spectrometry conditions in the liquid chromatography-mass spectrometry method include: Ion mode: ESI ion source, positive ion scanning mode; Detection mode: single ion scanning detection (Q1 MI); Curtain gas (CUR): 40psi; Declustering voltage (DP): 60 V; Injection voltage (EP): 5~15V; Collision chamber ejection voltage (CXP): 10 volts; Quantitative ion: 274.

1.

7. The method for detecting residual impurities in bilastine according to claim 6, characterized in that: The mass spectrometry conditions in the liquid chromatography-mass spectrometry method also include: Mass spectrometer: triple quadrupole tandem mass spectrometer; Ionization voltage (IS): 5000V; Ion source gas 1 (GS1): 55 psi; Auxiliary heating gas (GS2): 55psi; Ionization temperature (TEM): 550°C.

8. The method for detecting residual impurities in bilastine according to claim 7, characterized in that, The specific steps include: Prepare blank solution, standard series reference solution and test solution of bilastine API; The blank solution, the reference solution and the test solution are tested respectively by the liquid chromatography-mass spectrometry method; Draw a standard curve for the reference substance, and determine the content of the residual impurities in the test solution using the corresponding standard curve.

9. The method for detecting residual impurities in bilastine according to claim 8, characterized in that: The blank solution, reference solution and test solution are all prepared with 30% by volume acetonitrile aqueous solution.

Citation Information

Cited By

  • Method for detecting bilastine related substances

    CN119310218A

  • Method for analyzing content of 2-glycol ether and unknown impurities in bilastine starting material 2-ethoxychloroethane

    CN119715867A